Gilead Type 3 LQTS Study

Long QT syndrome (LQTS) is a hereditary disorder characterized clinically by prolongation of the QT interval on a standard 12-lead electrocardiogram (ECG), and by cardiac events such as syncope, aborted cardiac arrest, and sudden cardiac death. Type 3 LQTS (LQT3) is a subset of LQTS with a genetic mutation leading to an abnormal cardiac sodium channel. Patients who have been diagnosed with LQT3, and are between the ages of 18-70, may be eligible to participate in a clinical trial.

The purpose of the study is to evaluate an investigational drug for use in patients with LQT3, as it is believed that the risk of life-threatening cardiac events in patients with LQT3 is related to QT prolongation.

The study will consist of approximately 6 months of treatment, and will include multiple clinic visits during the course of the study. If eligible, participants may receive compensation for time and effort. Travel reimbursement will be provided to participants and an optional accompanying companion.

For more information, please visit clinicaltrials.gov or email LQT3@gilead.com.

Online Community
Find it Fast
Warning Signs
- Family history of unexpected, unexplained sudden death under age 40.
- Fainting or seizure during exercise, excitement or startle.
- Consistent or unusual chest pain &/or shortness of breath during exercise.

Gilead Type 3 LQTS Study

Online Community

Find it Fast

Warning Signs